Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

NCT03529175 is registered in ClinicalTrials.gov with CCTU- Cancer Theme as lead sponsor.

NCT NCT03529175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03529175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
CCTU- Cancer Theme
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2014
Completion date
June 30, 2016
Enrollment
146 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma metastatic